Table 1

Patient ID		1	2	3
Sex/age		M/39	F/47	F/34
BMI		20.8	22.1	25.1
TNM and Clinical Stage at Initial Diagnosis(AJCC 8th)		T3N2M0/III	T4N2M1/IVB	T3N1M0/III
Initial Treatment Regimen		ICT+RT	ICT+RT	CCT+RT
Date of Diagnosis for NPC		2003/11	2013/01	2014/04
Date of Diagnosis for BM		2011/05	2014/08	2015/03
Clinical Metastatic Status		Solitary metastasis	Oligometastasis	Widely metastases
		Metachronous	Synchronous	Metachronous
Site in the Brain		Temporal lobe	Occipital lobe/cerebellar	Parietal lobe/temporal lobe/occipital lobe
Number of Brain Lesions		1	2	3
Size of Brain Lesions（mm）		35×34	18×16/5×5	31×13/6×6/9×9
Extracranial Metastases		-	Lung	Lung/liver/ vertebrae / axilla/mediastinal/retro-peritoneum/inner mammary region
EBV-DNA at Diagnosis of BM（copies/ml）		397	0	56500
Treatment for BM	Surgery	√	-	√
	RT	-	WBRT: GTV 36Gy/12F,	IMRT: GTV 36Gy/12F, CTV 30Gy/12F
			CTV 30Gy/12F
	CT	-	ACT (Platinum + 5-FU + Tegafur)	CCT (5-FU 200mg/m2,10d)
Treatment for Extracranial Metastases		-	RT for lung	RT for liver, vertebral, lung, occipital and mediastinal; PCT（Platinum + 5-FU）
Overall Survival (Month)		171（alive）	132（alive）	125（alive）

Table 1: Clinical Characteristics and Treatment Regime of Patients.

CT: chemotherapy; RT: Radiation therapy; ICT: Induction chemotherapy; CCT: Concurrent chemotherapy; ACT: Adjuvant chemotherapy; PCT: Palliative chemotherapy; IMRT: Intensity-modulated radiation therapy; WBRT: Whole-brain radiation therapy

Table 2

First author	Year	No. of patients	Age	Sex	Histology type	Metastasis site	Systemic metastasis	Treatment	Disease-free survival after primary treatment	Overall survival (status at last follow-up)
Liaw et al.	1994	1	69	M	NKSSC	Bilateral occiptal regions	Bone	Systemic chemotherapy	?	7 months (alive)
R de Bree et al.	2001	2	64	F	SC	?	Lung	Radiotherapy	28 months	4 months
	2001		65	M	SC	?	No	Radiotherapy	4 months	3 months
Ngan et al.	2002	1	33	M	PDS	Left occipital lobe	Lung	Surgery	45 months	6 months
Gunn et al.	2004	1	49	M	PDS	Pituitary	No	Systemic therapy plus radiotherapy	8 months	7 months (alive)
Kaidar-Person et al.	2012	1	54	M	PDS	Occipital lobe	Lung	Radiotherapy (VMAT)	?	?
Elloumi et al.	2013	3	61	M	NKSSC	Cerebellum	Bone	Radiotherapy plus chemotherapy	?	4 months
	2013		47	M	NKSSC	Frontal lobe	Bone	Radiotherapy plus chemotherapy	?	3 months
	2013		39	M	NKSSC	Occipital lobe	Bone	Surgery	15 months	?
Geng et al.	2013	1	66	M	SC	Dural, cerebral hemispheres, cerebellum	Lung	WBRT, anti-angiogenesis therapy, and immunotherapy.	8 months	1 month
Kuo et al.	2014	1	37	F	DNK	Frontotemporal lobe	?	Surgery, radiotherapy and systemic therapy	8 months	24 months (alive)
Chunying Shen et al.	2017	1	47	M	NKSSC	Frontal lobe	Lung	Surgery plus systemic therapy	16 months	20 months
Park et al.	2019	2	49	F	?	Frontal lobe	?	SRS (Gamma Knife)	53 months	8 months
	2019		44	M	?	Cerebellar	?	Surgery plus systemic therapy	23 months	6 months
Su et al.	2019	1	43	M	NKSSC	B + FB	No	Radiotherapy plus chemotherapy	9 months	12 months (alive)
Chen et al.	2021	1	52	M		left temporal lobe	No	Surgery	72 months	18 months (alive)

Table 2: Literature Review.

Tables at a glance

Table 1

Table 2

Figures at a glance

Figure 1

FIGURE 1

Figure1: Magnetic resonance and pathological images of patients.